Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE® Smallpox Vaccine

        Print
| Source: Bavarian Nordic A/S
  * Ongoing contracts including options total more than 500,000 smallpox vaccine
    doses
  * First commercial contract after approval of IMVAMUNE in Canada

KVISTGAARD, Denmark, August 26, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that it has signed two contracts with the Canadian
authorities for the delivery of a total of 65,700 doses of IMVAMUNE smallpox
vaccine. The vaccines will be delivered in 2014 and 2015. This will bring the
current number of delivered doses of IMVAMUNE to Canada above 100,000 doses.

Following a public tender, the Public Health Agency of Canada has awarded
Bavarian Nordic a contract to deliver 45,700 doses of IMVAMUNE with the option
to deliver an additional 314,300 doses. This contract represents the first
commercial contract awarded by the Canadian authorities to Bavarian Nordic after
receiving approval of IMVAMUNE by Health Canada in 2013.

Secondly, the Canadian Department of National Defence, through exercise of an
option under an ongoing contract, has ordered 20,000 doses of IMVAMUNE smallpox
vaccine to replace the current stockpile for the Canadian Armed Forces. This
contract was awarded in 2008 with initial deliveries of 20,000 doses in 2009,
followed by a replacement order in 2012. Under this contract, an option of an
additional 140,000 doses remains.

Paul Chaplin, President & CEO of Bavarian Nordic said: "Having supplied our
smallpox vaccine for the armed forces since 2008, we are pleased to continue our
collaboration with the Canadian defense to address their biological
preparedness. We are also pleased to supply the first commercial quantities of
IMVAMUNE to the Public Health Agency of Canada following the approval in 2013 of
IMVAMUNE for use in a public health emergency in individuals who are
contraindicated to replicating smallpox vaccines."

The contracts do not affect the Company's financial guidance for 2014.


Contacts
Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About IMVAMUNE Smallpox Vaccine
IMVAMUNE is being developed as a safer smallpox vaccine for individuals who
should not receive traditional replicating vaccines, such as people with atopic
dermatitis (AD) and HIV. IMVAMUNE is the Company's most advanced clinical
program based on MVA-BN® - a robust and adaptable vaccine platform suitable for
addressing a wide variety of infectious diseases and cancer. Studies comprising
more than 7,400 subjects, including people diagnosed with AD or infected with
HIV, suggest that IMVAMUNE has a favorable safety profile. In 2013, the vaccine
was approved in Canada under the trade name IMVAMUNE and in the European Union
under the trade name IMVANEX®.

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial, and IMVAMUNE, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.


[HUG#1850925]